Decoy Therapeutics (FRA:FP11) E10: €-523,484.99 (As of Mar. 2026)


FRA:FP11 Decoy Therapeutics Inc FRA:FP11
23 GF Score
Price €5.23
! 3 Warning Signs
View Full Analysis

What is Decoy Therapeutics E10?

Decoy Therapeutics FRA:FP11 23 E10 is €-523,484.99 as of Mar. 2026. GuruFocus rates FRA:FP11 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Decoy Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-3.616. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-523,484.99 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-03), Decoy Therapeutics's current stock price is €5.232. Decoy Therapeutics's E10 for the quarter that ended in Mar. 2026 was €-523,484.99. Decoy Therapeutics's Shiller PE Ratio of today is .


Decoy Therapeutics  (FRA:FP11) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Decoy Therapeutics E10 Related Terms


Decoy Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Decoy Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Decoy Therapeutics E10 Chart

Decoy Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -1,526,230.64 -489,152.46

Decoy Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,570,863.72 -2,830,490.71 -659,610.72 -489,152.46 -523,484.99

FRA:FP11 vs ACUT, BIXT, CLDI: E10 Comparison

For the Biotechnology subindustry, Decoy Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Decoy Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Decoy Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Decoy Therapeutics's Shiller PE Ratio falls into.


FRA:FP11
23GF Score
Decoy Therapeutics Inc FRA:FP11
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Decoy Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Decoy Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-3.616/330.2130*330.2130
=-3.616

Current CPI (Mar. 2026) = 330.2130.

Decoy Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -561,843.798 241.018 -769,768.756
201609 -526,555.953 241.428 -720,196.584
201612 -416,068.510 241.432 -569,068.023
201703 -429,497.185 243.801 -581,726.711
201706 -412,427.077 244.955 -555,974.699
201709 -412,086.464 246.819 -551,320.229
201712 -357,058.352 246.524 -478,271.120
201803 -351,001.952 249.554 -464,450.209
201806 -387,420.122 251.989 -507,685.497
201809 -113,054.283 252.439 -147,885.208
201812 -88,295.550 251.233 -116,052.981
201903 -98,696.528 254.202 -128,208.577
201906 -39,986.291 256.143 -51,549.303
201909 -22,942.026 256.759 -29,505.315
201912 -13,556.311 256.974 -17,419.934
202003 -4,975.867 258.115 -6,365.752
202006 -3,902.515 257.797 -4,998.744
202009 -2,649.856 260.280 -3,361.829
202012 -2,691.030 260.474 -3,411.523
202103 -1,252.490 264.877 -1,561.436
202106 -2,091.600 271.696 -2,542.082
202109 -2,558.160 274.310 -3,079.500
202112 -2,867.400 278.802 -3,396.148
202203 -4,314.816 287.504 -4,955.786
202206 -2,996.928 296.311 -3,339.817
202209 -9,322.704 296.808 -10,371.951
202212 -3,738.240 296.797 -4,159.124
202303 -2,999.261 301.836 -3,281.235
202306 -1,902.303 305.109 -2,058.822
202309 -878.719 307.789 -942.738
202312 -4.952 306.746 -5.331
202403 -541.512 312.332 -572.514
202406 -396.311 314.175 -416.542
202409 -123.041 315.301 -128.860
202412 -174.626 315.605 -182.709
202503 -222.065 319.799 -229.296
202506 -70.227 322.561 -71.893
202509 -18.505 324.800 -18.813
202512 -14.412 324.054 -14.686
202603 -3.616 330.213 -3.616

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-523,484.99 mean?
Decoy Therapeutics (FRA:FP11) has a E10 of €-523,484.99 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Decoy Therapeutics and its competitors.
Is Decoy Therapeutics' E10 too high?
Decoy Therapeutics' current E10 is €-523,484.99. Overall, Decoy Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Decoy Therapeutics' E10 compare to ACUT and BIXT?
Decoy Therapeutics' E10 of €-523,484.99 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Decoy Therapeutics and its competitors. Decoy Therapeutics's current E10 is €-523,484.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decoy Therapeutics stock overvalued right now?
Decoy Therapeutics (FRA:FP11) has a current E10 of €-523,484.99. The current E10 is €-523,484.99. Decoy Therapeutics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Decoy Therapeutics (FRA:FP11), the current E10 is €-523,484.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Decoy Therapeutics Business Description

Other Exchanges DCOY:USA
Address 2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
23GF Score

Get the complete analysis for FRA:FP11

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.23
Price